Difference between revisions of "Tamoxifen"
From SDMRC
| (One intermediate revision by the same user not shown) | |||
| Line 8: | Line 8: | ||
==== Tamoxifen ==== | ==== Tamoxifen ==== | ||
| − | * | + | * 10mg/ml tamoxifen (final concentration) |
Tamoxifen from Sigma, catalogue number: [http://www.sigmaaldrich.com/catalog/product/sigma/t5648?lang=en®ion=US T5648]. | Tamoxifen from Sigma, catalogue number: [http://www.sigmaaldrich.com/catalog/product/sigma/t5648?lang=en®ion=US T5648]. | ||
| Line 35: | Line 35: | ||
=== Caution === | === Caution === | ||
| − | Tamoxifen injection and cre expression may be linked to a transient hypertrophy reaction in mice.<br /> | + | Tamoxifen injection and cre expression may be linked to a transient cardiac hypertrophy reaction in mice. Consider using cre-positive wildtype mice as controls.<br /> |
'''References:''' | '''References:''' | ||
# Cre-loxP DNA recombination is possible with only minimal unspecific transcriptional changes and without cardiomyopathy in [http://www.ncbi.nlm.nih.gov/pubmed/20802136 Tg(alphaMHC-MerCreMer)] mice. | # Cre-loxP DNA recombination is possible with only minimal unspecific transcriptional changes and without cardiomyopathy in [http://www.ncbi.nlm.nih.gov/pubmed/20802136 Tg(alphaMHC-MerCreMer)] mice. | ||
# Dilated cardiomyopathy resulting from high-level myocardial expression of [http://www.ncbi.nlm.nih.gov/pubmed/16762803?access_num=16762803&link_type=MED&dopt=Abstract Cre recombinase]. | # Dilated cardiomyopathy resulting from high-level myocardial expression of [http://www.ncbi.nlm.nih.gov/pubmed/16762803?access_num=16762803&link_type=MED&dopt=Abstract Cre recombinase]. | ||
# Avoidance of transient cardiomyopathy in cardiomyocyte-targeted [http://www.ncbi.nlm.nih.gov/pubmed/19520971 tamoxifen-induced MerCreMer gene deletion models.] | # Avoidance of transient cardiomyopathy in cardiomyocyte-targeted [http://www.ncbi.nlm.nih.gov/pubmed/19520971 tamoxifen-induced MerCreMer gene deletion models.] | ||
Latest revision as of 00:11, 11 November 2014
Contents
Tamoxifen injection protocol
Method Summary
This method describes how to induce expression of cre-recombinase in tamoxifen-inducible transgenic Cre-mouse lines.
Materials
Tamoxifen
- 10mg/ml tamoxifen (final concentration)
Tamoxifen from Sigma, catalogue number: T5648.
Sesame or Peanut Oil
use either sesame or peanut oil
- Sesame Oil from Sigma, catalogue number: S3547
- Peanut Oil missing link
Method
- Weigh in 100mg of tamoxifen
- Resuspend the tamoxifen in 1ml of ethanol (100%) and mix; (this step will take some time; if necessary warm to 37ºC for 20-30 minutes)
- After tamoxifen is dissolved, add 9ml of sesame or peanut oil
- Mix on shaker
- Aliquot and store until use at -20ºC
Injection protocol
- Inject intra-peritoneal (IP) using either of the following dosages:
- 20mg/kg/day over 6 days,
- 30mg/kg/day over 5 days, or
- 80mg/kg/day over 2 (to 3) days.
Caution
Tamoxifen injection and cre expression may be linked to a transient cardiac hypertrophy reaction in mice. Consider using cre-positive wildtype mice as controls.
References:
- Cre-loxP DNA recombination is possible with only minimal unspecific transcriptional changes and without cardiomyopathy in Tg(alphaMHC-MerCreMer) mice.
- Dilated cardiomyopathy resulting from high-level myocardial expression of Cre recombinase.
- Avoidance of transient cardiomyopathy in cardiomyocyte-targeted tamoxifen-induced MerCreMer gene deletion models.
